NEW YORK, Dec. 30, 2025 — AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or the “Company”), a clinical-stage biopharmaceutical company dedicated to improving patient outcomes through the development of effective, fast-acting, and accessible mental health treatments, today announced it has finalized the redomiciliation of its parent company from the Netherlands to a U.S. corporation established in Delaware. The move received approval from nearly 99% of the votes cast at the Company’s extraordinary general meeting of shareholders held on November 4, 2025.
The redomiciliation became effective after market close on the Nasdaq Global Market on December 30, 2025. Upon completion, all issued and outstanding ordinary shares of Atai Beckley N.V. were converted on a one-for-one basis into new shares of common stock of the Delaware-based entity, AtaiBeckley Inc. Shareholders of the former Dutch company are now stockholders of the U.S. corporation. The common stock of AtaiBeckley Inc. will maintain its listing on NASDAQ under the ticker symbol “ATAI”.
The Company anticipates that the redomiciliation will lead to cost savings, better align its corporate structure with its U.S. listing and investor base, simplify its organizational framework, and make reporting requirements more efficient, while also lessening the administrative load for both the Company and its investors.
Further details regarding the Company’s redomiciliation can be found in its filings with the Securities and Exchange Commission, accessible via its Investor Relations website.
About AtaiBeckley Inc.
AtaiBeckley is a clinical-stage biopharmaceutical company focused on transforming patient outcomes by creating effective, rapid-acting, and convenient treatments for mental health conditions. The company was established in November 2025 through the strategic merger of ATAI Life Sciences N.V. and Beckley Psytech Limited. Its portfolio of innovative therapies features BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD, and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, all currently in Phase 2 clinical trials. Additionally, the company is progressing a drug discovery initiative aimed at finding new, non-hallucinogenic 5-HT2AR agonists to address opioid use disorder and TRD. These efforts are designed to open new avenues in mental health care by delivering effective, scalable, and convenient interventional psychiatry treatments that can be easily incorporated into existing healthcare systems.
For the most recent news and to discover more about the AtaiBeckley mission, visit or follow the Company on and on .
Forward-Looking Statements
This press release includes statements that are considered forward-looking under the Private Securities Litigation Reform Act of 1995, as amended. The Company intends for these forward-looking statements to be protected by the safe harbor provisions set forth in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Terms such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “initiate,” “could,” “would,” “project,” “plan,” “potentially,” “preliminary,” “likely,” and comparable phrases are used to identify these forward-looking statements, though not all such statements contain these specific words. Forward-looking statements cover express or implied remarks concerning, but not limited to: the anticipated advantages of the redomiciliation; the Company’s business strategy and future plans; the potential, success, timing, and progress of clinical trials and associated milestones for its product candidates; and management’s plans and goals for future operations, research and development, and capital spending.
Forward-looking statements are not guarantees of future performance and are subject to known and unknown risks and uncertainties that may cause actual results to differ significantly from those projected. These include the important factors detailed in the “Risk Factors” section of the Company’s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”), which may be updated in subsequent filings. AtaiBeckley assumes no obligation to update or revise any forward-looking statements in this press release, except as required by law.
Contact Information
Investor Contact:
Media Contact:
